Gavin Y Oudit Selected Research

angiotensin I (1-7)

1/2020	Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.
12/2019	ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue.
1/2018	Angiotensin 1-7 stimulates brown adipose tissue and reduces diet-induced obesity.
1/2017	Recombinant Human ACE2 and the Angiotensin 1-7 Axis as Potential New Therapies for Heart Failure.
1/2017	Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.
7/2016	ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity.
4/2016	Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.
9/2015	Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2.
4/2014	Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity.
3/2014	Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gavin Y Oudit Research Topics

Disease

62	Heart Failure 01/2021 - 10/2003
36	Fibrosis (Cirrhosis) 10/2021 - 04/2002
29	Cardiomyopathies (Cardiomyopathy) 10/2021 - 09/2003
25	Inflammation (Inflammations) 01/2022 - 07/2007
21	Hypertrophy 10/2020 - 10/2003
20	Heart Diseases (Heart Disease) 10/2021 - 04/2002
14	Iron Overload 01/2019 - 09/2003
13	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 08/2010
12	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 02/2022 - 12/2005
12	Neoplasms (Cancer) 01/2021 - 10/2009
10	Hypertension (High Blood Pressure) 01/2020 - 06/2002
9	Myocardial Infarction 01/2022 - 09/2009
9	Insulin Resistance 01/2019 - 08/2012
8	Cardiomegaly (Heart Hypertrophy) 01/2019 - 10/2003
7	Cardiotoxicity 01/2022 - 01/2008
7	Obesity 01/2021 - 01/2016
6	Disease Progression 01/2022 - 03/2008
6	Vascular Diseases (Vascular Disease) 01/2019 - 01/2012
6	Hemochromatosis (Bronze Diabetes) 01/2019 - 05/2006
5	Reperfusion Injury 01/2020 - 05/2006
5	Type 2 Diabetes Mellitus (MODY) 11/2019 - 12/2008
5	Atherosclerosis 11/2019 - 10/2008
5	Fabry Disease (Fabry's Disease) 11/2018 - 03/2015
4	COVID-19 01/2022 - 01/2020
4	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2017
4	Ischemia 01/2020 - 09/2008
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2016 - 05/2006
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 12/2005
3	Rupture 01/2022 - 10/2010
3	Hypoxia (Hypoxemia) 01/2021 - 06/2002
3	Atrophy 01/2021 - 12/2005
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 02/2013
3	Abdominal Aortic Aneurysm 01/2020 - 12/2012
3	Pulmonary Arterial Hypertension 01/2020 - 01/2019
3	Body Weight (Weight, Body) 12/2019 - 04/2002
3	Infarction (Infarctions) 09/2015 - 09/2009
3	Diabetic Nephropathies (Diabetic Nephropathy) 04/2014 - 12/2008
3	Atrial Fibrillation 01/2014 - 11/2011
2	Wounds and Injuries (Trauma) 01/2022 - 01/2020
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2021 - 01/2019
2	Weight Loss (Weight Reduction) 01/2021 - 01/2019

Drug/Important Bio-Agent (IBA)

27	Angiotensin IIIBA 01/2022 - 06/2002
27	Angiotensin-Converting Enzyme 2IBA 01/2021 - 06/2002
15	AngiotensinsIBA 01/2022 - 07/2007
15	Matrix Metalloproteinases (MMPs)IBA 11/2018 - 08/2005
14	IronIBA 01/2019 - 09/2003
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2005
12	angiotensin I (1-7)IBA 01/2020 - 12/2008
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2012
11	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 07/2012
10	Peptides (Polypeptides)IBA 01/2022 - 12/2003
10	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 01/2008
9	ApelinIBA 01/2022 - 01/2012
8	CollagenIBA 01/2022 - 10/2010
8	EnzymesIBA 10/2020 - 03/2015
8	CytokinesIBA 01/2018 - 08/2005
7	Metalloproteases (Metalloproteinases)IBA 01/2022 - 08/2010
7	Insulin (Novolin)FDA Link 01/2019 - 08/2012
7	Irbesartan FDA LinkGeneric 12/2016 - 07/2007
6	DisintegrinsIBA 01/2022 - 09/2015
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2018 - 08/2005
6	Superoxides (Superoxide)IBA 12/2017 - 03/2010
6	NADPH Oxidases (NAD(P)H oxidase)IBA 08/2014 - 07/2007
5	Fibronectins (Fibronectin)IBA 01/2022 - 12/2009
5	Protein Isoforms (Isoforms)IBA 10/2020 - 01/2013
5	ResveratrolIBA 01/2018 - 02/2013
5	Therapeutic UsesIBA 02/2016 - 01/2012
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 03/2017
4	Phosphatidylinositols (Phosphatidylinositol)IBA 10/2020 - 10/2003
4	Pharmaceutical PreparationsIBA 12/2019 - 01/2013
4	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2019 - 10/2003
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 07/2012
4	Tissue Inhibitor of Metalloproteinase-3IBA 10/2018 - 08/2005
4	Tissue Inhibitor of MetalloproteinasesIBA 10/2018 - 08/2010
4	ApolipoproteinsIBA 12/2017 - 10/2008
3	Apelin ReceptorsIBA 01/2022 - 01/2017
3	LipidsIBA 01/2022 - 12/2007
3	Atrial Natriuretic Factor (ANF)IBA 01/2021 - 09/2013
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 01/2013
3	Adrenergic Agents (Adrenergic Drugs)IBA 01/2019 - 12/2007
3	Oxidoreductases (Dehydrogenase)IBA 01/2019 - 09/2009
3	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2018 - 02/2011
3	Retinaldehyde (Retinal)IBA 01/2018 - 12/2014
3	GalactosidasesIBA 01/2018 - 03/2015
3	Messenger RNA (mRNA)IBA 01/2017 - 07/2014
3	AdiponectinIBA 07/2016 - 02/2013
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/2014 - 12/2008
3	Phosphotransferases (Kinase)IBA 02/2011 - 12/2007
2	human ERBB2 proteinIBA 01/2022 - 01/2019
2	ReninIBA 01/2022 - 07/2012
2	Troponin IIBA 10/2021 - 01/2017
2	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2021 - 11/2018
2	Extracellular Matrix ProteinsIBA 10/2021 - 01/2017
2	GelsolinIBA 10/2021 - 12/2018
2	CholesterolIBA 01/2021 - 01/2016
2	Tissue Inhibitor of Metalloproteinase-4IBA 01/2021 - 07/2014
2	AlpelisibIBA 01/2021 - 01/2019

Therapy/Procedure

43	Therapeutics 11/2021 - 08/2005
5	Drug Therapy (Chemotherapy) 01/2021 - 07/2007
3	Heart-Assist Devices 02/2022 - 01/2016